Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 3/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 15/20 | 0.43 |
| ▸ | IKBKB | O14920 | 1/20 | 0.38 |
| ▸ | CDK2AP1 | O14519 | 3/20 | 0.36 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.36 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.36 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2283601 | 1.00 | MAPK14 (0.46) | MAPK14CHEK1IKBKBCDK2AP1MAPK13 | |
| SCHEMBL2282357 | 0.97 | CHEK1 (0.46) | MAPK14CHEK1IKBKBCDK2AP1MAPK13 | |
| SCHEMBL2282350 | 0.97 | CHEK1 (0.46) | MAPK14CHEK1IKBKBCDK2AP1MAPK13 | |
| SCHEMBL2279699 | 0.90 | CHEK1 (0.55) | MAPK14CHEK1IKBKBCDK2AP1 | |
| SCHEMBL2279696 | 0.90 | CHEK1 (0.55) | MAPK14CHEK1IKBKBCDK2AP1 | |
| SCHEMBL2280905 | 0.87 | CHEK1 (0.48) | CHEK1IKBKB | |
| SCHEMBL2278399 | 0.87 | CHEK1 (0.59) | MAPK14CHEK1IKBKBCDK2AP1 | |
| SCHEMBL2278395 | 0.87 | CHEK1 (0.59) | MAPK14CHEK1IKBKBCDK2AP1 | |
| SCHEMBL2286875 | 0.86 | CHEK1 (0.45) | MAPK14CHEK1IKBKBMAPK13MAPK12 | |
| SCHEMBL2286880 | 0.86 | CHEK1 (0.45) | MAPK14CHEK1IKBKBMAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2078007-B1 | IKK-BETA SERINE-THREONINE PROTEIN KINASE INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2011-08-31 | — | — | EP | disclosed |
| US-8003695-B2 | IKK-beta serine-threonine protein kinase inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2011-08-23 | — | — | US | disclosed |
| US-20100087515-A1 | IKK-BETA SERINE-THREONINE PROTEIN KINASE INHIBITORS | Chroma Terapeutics Ltd (GB) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087515-A1 | IKK-BETA SERINE-THREONINE PROTEIN KINASE INHIBITORS | IRAK3, IKBKE, IRAK1 | MAPK14 654/4885CHEK1 204/4885IKBKB 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.